COO
Cooper Companies (The)
Health Care · Health Care Supplies · US
$67.34
Data: 2026-05-15
✓ ETHICAL PASS

NARROW MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$11.7B
Total market value of the company
Trailing P/E
29.80
Premium valuation
Forward P/E
11.93
Based on estimated future earnings — lower means cheaper
Rev Growth
+6.2%
Year-over-year revenue change
Profit Margin
9.7%
How much profit the company keeps from each dollar of revenue
ROE
4.9%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$91.07
+35% from current price — median analyst estimate
Recommendation
NONE
Consensus view from 15 analysts covering this stock
About Cooper Companies (The)

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

https://www.coopercos.com

Country: United States Employees: 15,000 Industry: Medical Instruments & Supplies
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
20.2% PASS
Debt must be below 33% of total assets
Cash Ratio
0.0% PASS
Interest-bearing cash below 33% of assets
Receivables
7.6% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Fair Value Est.
$60.25
What our model estimates this business is worth per share
Margin of Safety
-11.8%
Trading above fair value — no margin of safety
Rating
OPPORTUNITY
Overall assessment combining ethics, valuation, and quality
Percentile
97.6th
Ranks in the top 2% of our 13,571 screened universe
Ethical Score
90.4
Valuation Score
77.5
Quality Score
45.3
Combined
74.4

Trading near fair value at $60 (estimated $60). Passes all ethical screens. Ranks better than 94% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKDOWN
Price trending down — defensive positioning
Sharpe Ratio
-0.482
Returns do not compensate for the risk — negative edge
Kelly Fraction
-0.0480
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.381
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-17.9%
Historical annualised return based on price data
Max Drawdown
-47.0%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
165
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.89
Less volatile than the market — more defensive
52W High
$89.83
25% below the year high
52W Low
$58.89
14% above the year low
Avg Volume
2,117,812
Average daily shares traded — higher means easier to buy and sell
Short Ratio
2.6
Days it would take all short sellers to cover — higher means more crowded
Short % Float
3.2%
Low short interest — limited bearish positioning
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$2.01
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.33
Conservative use of debt — low financial risk
Current Ratio
1.34
Adequate but worth monitoring
Quick Ratio
0.58
Like current ratio but excludes inventory — stricter test
Gross Margin
65.4%
Revenue left after cost of goods — higher means pricing power
Operating Margin
20.8%
Profit from core operations before interest and tax
Free Cash Flow
$367M
Positive — the business generates more cash than it spends
Revenue (TTM)
$4.2B
Total revenue over the last 12 months
Net Income
$401M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
15
Target High
$103.00
Target Median
$91.07
Target Low
$69.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

55
NEUTRAL
Mixed insider activity. 0 purchases and 0 sales in the last 90 days — no clear directional signal. Politicians have been buying this name.
Date Insider Title Type Shares Value
2026-04-01 MADDEN TERESA SMITH Director 3,322 —
2026-04-01 WEISS ROBERT S Director 3,654 —
2026-04-01 LUCCHESE CYNTHIA L Director 3,322 —
2026-04-01 ROSEBROUGH WALTER M JR Director 832 —
2026-04-01 RIVAS MARIA Director 3,322 —
2026-04-01 CARBONE BARBARA Director 3,050 —
2026-04-01 KURZIUS LAWRENCE ERIK Director 3,322 —
2026-04-01 JAY COLLEEN E Director 3,322 —
2026-01-12 JAY COLLEEN E Director 7,064 $278,322
2026-01-08 MCBRIDE DANIEL G Chief Operating Officer 12,887 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2026-04-13 Ro Khanna Democrat Purchase 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry Indicators Options Calendar Composites Boycott Tracker Is It Halal? Earnings Calendar Dividend Screener Country Guides Glossary Join Free →

Get our weekly market brief free.